ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Pain profiles in pancreatic cancer and chronic pancreatitis: a multicenter cross-sectional analysis.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Abnormal pain processing has been associated with impaired patient-reported outcomes (PROMs) in chronic pancreatitis (CP), but its clinical relevance in pancreatic ductal adenocarcinoma (PDAC) remains unclear. We investigated the association between P-QST-defined hyperalgesia and pain-related, psychological, and quality-of-life outcomes in patients with painful PDAC and compared these associations with CP. Methods: This multicenter cross-sectional analysis included patients with painful CP and PDAC at five tertiary referral hospitals in Denmark, Germany and the USA. Based on the results of pancreatic quantitative sensory testing (P-QST), patients were classified into three subgroups according to hyperalgesia status: no hyperalgesia, reflecting normal pain processing; segmental hyperalgesia at the pancreatic dermatome, suggesting abnormal spinal pain processing; widespread hyperalgesia, indicative of pathological pain processing across the entire neuraxis. PROMs included the Brief Pain Inventory (BPI), Pain Catastrophizing Scale (PCS), Hospital Anxiety and Depression Scale (HADS), and EORTC QLQ-C30. Between-disease P-QST analyses were adjusted for age, sex, and regular opioid use. Exploratory disease-by-hyperalgesia interaction analyses assessed whether associations between hyperalgesia and selected PROMs differed between CP and PDAC. Results: A total of 275 patients (153 CP, 122 PDAC) were enrolled. Hyperalgesia was present in 53.6% of patients with CP and 43.8% of patients with PDAC, with no statistically significant difference after multivariable adjustment (aOR 0.75, 95% CI 0.43-1.33; Conclusion: Although altered pain processing was frequent in painful PDAC, its association with patient-reported outcomes differed from that observed in CP. In particular, hyperalgesia showed a disease-specific relationship with pain-related functional impairment. These findings suggest that the clinical meaning of P-QST-defined hyperalgesia in PDAC cannot simply be inferred from CP and support further PDAC-specific studies linking pain phenotype to patient-reported burden and treatment response and pain management approaches might not be transferable across diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.